Shares of commercial-stage biopharmaceutical company BridgeBio Pharma (NASDAQ: BBIO) fell hard recently after it reported a surprising clinical trial failure. The company's highly valued new drug candidate failed to hit the primary endpoint in a pivotal study.
Luckily, there are more clinical-stage candidates coming through the pipeline. Let's look at the strength of BridgeBio's overall pipeline to see if this biotech stock is a buy at its knocked-down price.
Image source: Getty Images.
For further details see:
Is BridgeBio Pharma Stock a Buy on the Dip?